← X4 Pharmaceuticals, Inc (XFOR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
X4 Pharmaceuticals, Inc (XFOR)
Biological Products, (No Diagnostic Substances) · market cap $312M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
X4 Pharmaceuticals (XFOR) is a small-cap biotech with 143 employees and a $372M market cap, focused primarily on mavorixafor, a Phase 3 asset targeting WHIM Syndrome — a rare, genetically defined primary immunodeficiency. The company carries $216.9M in cash (roughly 33 months of runway) against a net cash position of $141.9M, providing meaningful balance sheet support, though a persistent operating burn of ~$70–80M annually keeps dilution risk elevated.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| X4P-001 | Phase 2 | WHIM Syndrome |
| Mavorixafor | Phase 3 | WHIM Syndrome |
| axitinib | Phase 2 | Clear Cell Renal Cell Carcinoma |
Price & technical context
3-month
-31.5%
6-month
-34.9%
12-month
-17.3%
52-wk range
$2.83–$4.67
vs 50-day MA
-26.1%
vs 200-day MA
-27.6%
Realized vol
74.2%
Max drawdown
-94.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for XFOR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.